FSME IMMUN NEW Follow-Up to Study 199 in Children Aged 1 to 6 Years
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three treatment groups of Baxter study 199 (a dose-finding study to investigate the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy subjects aged 1 to 6 years).
| Condition | Intervention | Phase |
|---|---|---|
|
Encephalitis, Tick-Borne |
Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind |
| Official Title: | Follow-Up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 1 to 6 Years |
Eligibility| Ages Eligible for Study: | 1 Year to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
All volunteers who participated in Baxter study 199 and received two vaccinations will be invited to participate. Male and female children will be eligible for participation in this study if:
- They received two vaccinations with one of the three different dosages of FSME IMMUN NEW during the course of Baxter study 199
- Written informed consent from the legal guardian is available.
Exclusion Criteria:
There are no specific exclusion criteria for this study entry. However volunteers will be assessed for eligibility to receive a third vaccination.
Volunteers will be excluded from vaccination and consecutive visits in this study if they:
- Are not clinically healthy, (i. e. the physician would have reservations vaccinating with FSME IMMUN NEW outside the scope of a clinical trial)
- Have already been administered a third TBE vaccination elsewhere after the two vaccinations in Baxter study 199
- Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 199
- Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions
- Have received banked human blood or immunoglobulins within one month of study entry
- Are known to be HIV positive (a special HIV test is not required for the purpose of the study) since the last visit of Baxter study 199
- Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in Baxter study 199
- Had received an investigational new drug within 6 weeks prior to study start
Contacts and Locations| Austria | |
| Grieskirchner Strasse 17 | |
| Wels, Austria, A-4600 | |
| Germany | |
| Neuschwanstein Strasse 5 | |
| Augsburg, Germany, D-86163 | |
| Marktplatz 33 | |
| Bad Saulgau, Germany, D-88348 | |
| Hauptstrasse 9 | |
| Bietigheim-Bissingen, Germany, D-74321 | |
| Salzgasse 11 | |
| Calw, Germany, D-75365 | |
| Mohrenstrasse 8 | |
| Coburg, Germany, D-96450 | |
| Bahnhofstrasse 1 | |
| Elzach, Germany, D-79215 | |
| Rheinstrasse 1a | |
| Ettenheim, Germany, D-77955 | |
| Ehlerstrasse 17 | |
| Friedrichshafen, Germany, D-88046 | |
| Peter-Seifert Strasse 5 | |
| Gersfeld, Germany, D-36129 | |
| Solothumer Strasse 2 | |
| Heilbronn, Germany, D-74072 | |
| Hauptstrasse 240 | |
| Kehl, Germany, D-77694 | |
| Schwarzwald Strasse 20 | |
| Kirchzarten, Germany, D-79199 | |
| Altoettinger Strasse 3 | |
| Landsberg, Germany, D-86899 | |
| Rastatter Strasse 7 | |
| Mannheim-Secken, Germany, 68239 | |
| Wilhelmstrasse 25 | |
| Metzingen, Germany, D-72555 | |
| Dohmbuehler Strasse 8 | |
| Nuernberg, Germany, D-90449 | |
| Glogauer Strasse 15 | |
| Nuernberg, Germany, D-90473 | |
| Tuchbergstrasse 2 | |
| Oberndorf/Neckar, Germany, D-78727 | |
| Asternweg 11a | |
| Offenburg, Germany, D-77656 | |
| Wilhelmstrasse 7 | |
| Offenburg, Germany, D-77654 | |
| Bergstrasse 27 | |
| Rottweil, Germany, D-78628 | |
| Berneckstrasse 19 | |
| Schramberg, Germany, D-78713 | |
| Hauptstrasse 11 | |
| Tegernsee, Germany, D-83681 | |
| Broner Platz 6 | |
| Weingarten, Germany, D-88250 | |
| Principal Investigator: | Baxter BioScience Investigator | Baxter Healthcare Corporation |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00161850 History of Changes |
| Other Study ID Numbers: | 206 |
| Study First Received: | September 8, 2005 |
| Last Updated: | June 12, 2006 |
| Health Authority: | Germany: Paul-Ehrlich-Institut |
Additional relevant MeSH terms:
|
Encephalitis, Tick-Borne Encephalitis Central Nervous System Viral Diseases Virus Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections |
Encephalitis, Arbovirus Arbovirus Infections Tick-Borne Diseases Encephalitis, Viral RNA Virus Infections Flavivirus Infections Flaviviridae Infections |
ClinicalTrials.gov processed this record on May 21, 2013